Login to Your Account



Annexin Pharma lines up annexin A5 for vascular disorders

By Cormac Sheridan
Staff Writer

Tuesday, April 25, 2017

DUBLIN – Annexin Pharmaceuticals AB completed a listing on the First North exchange in Stockholm last week and is on track to begin clinical trials of its first-in-class therapy for inflammatory vascular disease by year-end.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription